To test if NID1 may have a similar effect on other organ systems, therefore potentially supporting a regenerative therapy that is otherwise hindered by ischemic conditions, we choose a model of pancreatic beta cell transplantation, which is a therapy for type 1 diabetes where up to 60% of beta‐cell‐containing islets fail to engraft due to ischemia at the transplant location and the adverse reaction of the immune system.[14] Here, we demonstrated the protective and functional effect of NID1 on pancreatic beta cells in an ischemia model. The gene discussed is NID1; the disease is type 1 diabetes mellitus.